Biomedical literature, made navigable
Discover articles through diseases, drugs, treatments, interventions, clinical instruments, institutions and funders extracted from the BMJ open corpus.
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentionsChoose an entity to see the articles in which it was identified.
… syndrome or intestinal failure. 100% (25/25) patients received Ferric carboxymaltose. No acute infusion-related reactions occurred. Twelve patients …
…topical corticosteroids, and more recently, to biologic agents. Budesonide remains a widely adopted corticosteroid treatment, while dupilu…
…y, meeting the IBD Standards UK guidelines. However, paediatric IBD patients experience a delay from primary care (GP) referral, wi…
… (VEOIBD) have been reported to have decreased response rate to infliximab. Younger children have unique drug pharmacokinetics, which risk…
…5% CI 0.454-0.945, p=0.024), were independently associated with UDCA treatment failure (IDDF2026-ABS-0398 Figure 1).Conclusions Earl…
…Introduction Mortality from liver disease is rising, largely driven by high levels of alcohol consumption…
…ation - 43% (9/21) on a DOAC, 48% (10/21) on LMWH, 9% (2/21) on warfarin. 67% (6/9) were discharged on their original DOAC and 50% (1/2)…
…prophylactic therapies, including tricyclic antidepressants and topiramate, are endorsed by the American Neurogastroenterology and Motilit…
…Objective Guselkumab (GUS) is a dual-acting IL-23p19 inhibitor that neutralises IL-2…
…-23 signaling. Front. Immunol. 2025;16:1532852.Rubin DT, et al. Guselkumab in patients with moderately to severely active ulcerative colit…
…Introduction Infliximab (IFX) improves outcomes in Inflammatory Bowel Disease; however secondary loss of response (LOR) occurs in up to 60% o…